BioCentury | Jan 18, 2010
Clinical News

CXB722: Phase I data

...In a Phase I trial in 24 healthy volunteers, CXB722 significantly reduced several neuroendocrine biomarkers that...
...exhibited the expected elevations in the biomarkers. CXB722 also lowered heart rate elevation vs. placebo. CXB722...
...American College of Neuropsychopharmacology meeting in Hollywood, Fla. CeNeRx BioPharma Inc. , Cary, N.C. Product: CXB722...
Items per page:
1 - 1 of 1